Mark has served as Chairman of Apogee since August 2023. Mark previously served as Chairman, President and Chief Executive Officer of Prometheus Biosciences (Nasdaq: RXDX) from 2019-2023. Prometheus Biosciences was a clinical-stage biotechnology company which created the first precision therapeutics for immune-mediated diseases and was acquired by Merck for $10.8B in June 2023. Mr. McKenna brings more than 20+ years of experience and strategic leadership from the Pharmaceutical, Medical Device, MedTech, Consumer and Diagnostics sectors.
While at Prometheus, Mr. McKenna raised more than a $1 billion in private and public financing, led the top performing biotech IPO of 2021 and top performing biotech stock of 2022 and 2023(prior to transaction close). Early investors of Prometheus earned more than 25X return on capital. Mr. McKenna currently serves as Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office dedicated to investing in breakthrough treatments for debilitating diseases.
Prior to Prometheus, Mr. McKenna was a corporate officer of Bausch Health and served as President of the subsidiary Salix Pharmaceuticals. There he revitalized the gastroenterology business with a series of strategic acquisitions and product launches, doubling revenue to exceed $2 billion while enhancing operating margins. Earlier, Mr. McKenna served at Bausch + Lomb for more than a decade, most recently as SVP and General Manager of the US Vision Care business where he significantly grew revenue by 22% CAGR in an otherwise flat market. He began his career at Johnson & Johnson and held several positions of increasing responsibility. Mr. McKenna holds a degree in Marketing from Arizona State University and a MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton’s Fellows program at the University of Pennsylvania school of business.
Mr. McKenna is passionate about solving big problems in medicine and is regularly featured on CNBC’s Mad Money and Bloomberg radio. In addition, Mr. McKenna is a frequent guest speaker at the Longwood Healthcare conference and other industry thought-leader events. In 2023, he was selected as EY’s Entrepreneur of the year, recognizing his contributions to advancement of entrepreneurship and science.
What is Mark C. Mckenna's net worth?
The estimated net worth of Mark C. Mckenna is at least $817,300.00 as of December 12th, 2024. Mckenna owns 20,000 shares of Apogee Therapeutics stock worth more than $817,300 as of March 14th. This net worth approximation does not reflect any other investments that Mckenna may own. Learn More about Mark C. Mckenna's net worth.
How do I contact Mark C. Mckenna?
The corporate mailing address for Mckenna and other Apogee Therapeutics executives is 221 Crescent Street, Building 17 Suite 102b, Waltham, MA 02453, United States. Apogee Therapeutics can also be reached via phone at 650-394-5230 and via email at investors@apogeetherapeutics.com. Learn More on Mark C. Mckenna's contact information.
Has Mark C. Mckenna been buying or selling shares of Apogee Therapeutics?
Mark C. Mckenna has not been actively trading shares of Apogee Therapeutics during the last quarter. Most recently, on Thursday, December 12th, Mark C. Mckenna bought 20,000 shares of Apogee Therapeutics stock. The stock was acquired at an average cost of $49.54 per share, with a total value of $990,800.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company's stock, valued at $990,800. Learn More on Mark C. Mckenna's trading history.
Who are Apogee Therapeutics' active insiders?
Are insiders buying or selling shares of Apogee Therapeutics?
In the last year, Apogee Therapeutics insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $990,800.00. In the last year, insiders at the sold shares 20 times. They sold a total of 264,725 shares worth more than $12,378,800.40. The most recent insider tranaction occured on March, 5th when insider Carl Dambkowski sold 1,590 shares worth more than $48,463.20. Insiders at Apogee Therapeutics own 36.1% of the company.
Learn More about insider trades at Apogee Therapeutics. Information on this page was last updated on 3/5/2025.
